Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases

Abstract

Non-canonical nuclear factor kappa B (NF-κB) signaling pathway regulates many physiological and pathological processes, including liver homeostasis and diseases. Recent studies demonstrate that non-canonical NF-κB signaling pathway plays an essential role in hyperglycemia, non-alcoholic fatty liver disease, alcoholic liver disease, liver regeneration, liver injury, autoimmune liver disease, viral hepatitis, and hepatocellular carcinoma. Small-molecule inhibitors targeting to non-canonical NF-κB signaling pathway have been developed and shown promising results in the treatment of liver injuries. Here, the recent advances and future prospects in understanding the roles of the non-canonical NF-κB signaling pathways in the regulation of liver diseases are discussed.

Current Therapies for Cholestatic Diseases

“…The reduction in fibrosis is achieved by the activation of PPARα and PPARδ that lead to the inhibition of NF-κB and AP-1 pathways. These two pathways are related to liver damage and inflammation [ 69 , 70 , 71 ].…”

Current Therapies for Cholestatic Diseases

“…The reduction fibrosis is achieved by the activation of PPARα and PPARδ that lead to the inhibition of NF-κB and AP-1 pathways. These two pathways are related to liver damage and inflammation [66,67].…”